CH651042A5 - Derives de la theophylline et de la theobromine, procede pour leur preparation et compositions pharmaceutiques contenant ces derives. - Google Patents
Derives de la theophylline et de la theobromine, procede pour leur preparation et compositions pharmaceutiques contenant ces derives. Download PDFInfo
- Publication number
- CH651042A5 CH651042A5 CH5675/81A CH567581A CH651042A5 CH 651042 A5 CH651042 A5 CH 651042A5 CH 5675/81 A CH5675/81 A CH 5675/81A CH 567581 A CH567581 A CH 567581A CH 651042 A5 CH651042 A5 CH 651042A5
- Authority
- CH
- Switzerland
- Prior art keywords
- group
- formula
- ethanol
- compound
- atom
- Prior art date
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 title claims description 34
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 229960000278 theophylline Drugs 0.000 title description 89
- -1 m-methoxyphenyl group Chemical group 0.000 claims description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 241001331845 Equus asinus x caballus Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 188
- 229960004559 theobromine Drugs 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 70
- 238000000354 decomposition reaction Methods 0.000 description 29
- 239000002904 solvent Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 21
- 238000002844 melting Methods 0.000 description 21
- 230000008018 melting Effects 0.000 description 21
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 18
- 238000001953 recrystallisation Methods 0.000 description 16
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000009471 action Effects 0.000 description 10
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 9
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 210000002385 vertebral artery Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001105 femoral artery Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTIKWCAWHQZPSP-UHFFFAOYSA-N 3-methyl-1-(1-methylcyclohexa-2,4-dien-1-yl)piperazine Chemical compound CC1(CC=CC=C1)N1CC(NCC1)C MTIKWCAWHQZPSP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000003236 psychic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KLWQGZODUQLBCJ-UHFFFAOYSA-N 1-(5-bromopentyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCBr)C(=O)C2=C1N=CN2C KLWQGZODUQLBCJ-UHFFFAOYSA-N 0.000 description 1
- WTSBEXZNHFHRFY-UHFFFAOYSA-N 1-(7-bromoheptyl)-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCCCBr)C(=O)C2=C1N=CN2C WTSBEXZNHFHRFY-UHFFFAOYSA-N 0.000 description 1
- IMAWRJZYXYLGBL-UHFFFAOYSA-N 2-methoxy-1-phenylpiperazine Chemical compound COC1CNCCN1C1=CC=CC=C1 IMAWRJZYXYLGBL-UHFFFAOYSA-N 0.000 description 1
- VWWPKTKFHSCILU-UHFFFAOYSA-N 3-(hydroxymethyl)-7-methylpurine-2,6-dione Chemical compound C(O)N1C(NC(C=2N(C=NC1=2)C)=O)=O VWWPKTKFHSCILU-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- ZZWGXGHWFOTKNP-UHFFFAOYSA-N 7-(2-bromoethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCBr)C=N2 ZZWGXGHWFOTKNP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid group Chemical group C(\C=C/C(=O)O)(=O)O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid group Chemical group C(CC(=O)O)(=O)O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55121712A JPS5746983A (en) | 1980-09-04 | 1980-09-04 | Theophylline derivative and its preparation |
| JP12171380A JPS5746984A (en) | 1980-09-04 | 1980-09-04 | Theobromine derivative and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH651042A5 true CH651042A5 (fr) | 1985-08-30 |
Family
ID=26459005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH5675/81A CH651042A5 (fr) | 1980-09-04 | 1981-09-03 | Derives de la theophylline et de la theobromine, procede pour leur preparation et compositions pharmaceutiques contenant ces derives. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US4426383A (enExample) |
| CA (1) | CA1172632A (enExample) |
| CH (1) | CH651042A5 (enExample) |
| DE (1) | DE3134929A1 (enExample) |
| ES (1) | ES8303411A1 (enExample) |
| FR (1) | FR2489331A1 (enExample) |
| GB (1) | GB2083470B (enExample) |
| IT (1) | IT1138196B (enExample) |
| NL (1) | NL8104073A (enExample) |
| SE (2) | SE456910B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
| ES506046A0 (es) * | 1981-10-06 | 1983-02-01 | Invest Tecnica Aplicada | Procedimiento de obtencion de nuevas xantinas con actividad farmacologica |
| FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| IT1203656B (it) * | 1983-06-10 | 1989-02-15 | Medosan Ind Biochimi | Attivita' antiaggregante piastrinica,antiinfiammatoria e broncolitica di esteri aroilpirrol e pirrilfenil acetici delle 7 (w-ossialchil) teofilline |
| US4548939A (en) * | 1984-10-01 | 1985-10-22 | Janssen Pharmaceutica N. V. | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
| HU198052B (en) * | 1986-02-14 | 1989-07-28 | Sandoz Ag | Process for producing purine derivatives substituted by side chain containing piperazinyl ring and pharmaceutical compositions comprising such compounds |
| US4710572A (en) * | 1986-07-30 | 1987-12-01 | American Home Products Corporation | Histamine H1 antagonists |
| US4716165A (en) * | 1986-09-24 | 1987-12-29 | American Home Products Corporation | Histamine H1 antagonists |
| US4716166A (en) * | 1986-10-21 | 1987-12-29 | American Home Products Corporation | Histamine H1 antagonists |
| JP2552494B2 (ja) * | 1987-04-08 | 1996-11-13 | ヘキストジャパン株式会社 | イミダゾチアジアジン誘導体及びその製造法 |
| FR2618151B1 (fr) * | 1987-07-16 | 1991-01-11 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique |
| US5021574A (en) * | 1988-03-03 | 1991-06-04 | Ortho Pharmaceutical Corporation | 6-substituted purinyl piperazine derivatives |
| US4876257A (en) * | 1988-03-03 | 1989-10-24 | Ortho Pharmaceutical Corporation | 6-Substituted purinyl piperazine derivatives useful as cardiotonic and antiarrhythmic agents |
| US5164390A (en) * | 1988-03-03 | 1992-11-17 | Ortho Pharmaceutical Corporation | 6-substituted purinyl piperazine derivatives |
| US5332733A (en) * | 1990-11-24 | 1994-07-26 | Kali-Chemie Pharma Gmbh | Heterocyclically substituted piperazinoakylbenzoxazine and piperazinoalkylbenzothiazine compounds, processes for preparing them, and medicaments containing them |
| US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| AU9002598A (en) | 1997-09-16 | 1999-04-05 | Takeda Chemical Industries Ltd. | Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs |
| WO1999031101A1 (en) * | 1997-12-17 | 1999-06-24 | University Of South Florida | Adenosine receptor antagonists with improved bioactivity |
| US6979687B1 (en) * | 2002-09-27 | 2005-12-27 | Ing-Jun Chen | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities |
| US20050209243A1 (en) * | 2002-09-27 | 2005-09-22 | Ing-Jun Chen | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities |
| CN1809545A (zh) * | 2003-06-20 | 2006-07-26 | 艾尼纳制药公司 | N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法 |
| US20050026848A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| US20090285899A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| EP1844792A4 (en) * | 2004-12-14 | 2008-05-21 | Shionogi & Co | THERAPEUTIC AGENT AGAINST OBSTIPATION |
| PL2159226T3 (pl) * | 2007-03-29 | 2017-02-28 | Joint-Stock Company "Obninsk Chemical Pharmaceutical Company" | Środek antyhistaminowy i antyalergiczny oraz sposób jego wytwarzania |
| CA2691468C (en) * | 2007-06-22 | 2017-05-09 | Hydra Biosciences, Inc. | Substituted xanthine compounds and methods to treat diseases mediated by trpa1 |
| WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
| TWI368511B (en) * | 2009-04-30 | 2012-07-21 | Univ Kaohsiung Medical | Synthesis and pharmacokinetic activities of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives |
| TWI368513B (en) * | 2009-04-30 | 2012-07-21 | Univ Kaohsiung Medical | Synthesis of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives, and rhokinase-dependent inhibition activity on pulmonary artery endothelium dysfunction, medial wall thickness and vascular obstruction thereof |
| US8470805B2 (en) * | 2009-04-30 | 2013-06-25 | Kaohsiung Medical University | Processes for preparing piperazinium salts of KMUP and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR882044A (fr) * | 1940-05-03 | 1943-05-14 | Bosch Gmbh Robert | Procédé de fabrication de graisses lubrifiantes |
| GB1133989A (en) * | 1964-12-08 | 1968-11-20 | Chugai Pharmaceutical Co Ltd | Theophylline derivatives, their salts and process for preparing the same |
| DE1620576A1 (de) | 1966-11-25 | 1970-02-26 | Troponwerke Dinklage & Co | Verfahren zur Herstellung von Theophyllin- und Theobrominverbindungen |
| CA975367A (en) * | 1972-03-20 | 1975-09-30 | John D. Mccoll | Preparation of 7-propyl substituted theophyllines |
| JPS55118488A (en) * | 1979-03-05 | 1980-09-11 | Eisai Co Ltd | Theobromine derivative and its preparation |
| DE2922159A1 (de) | 1979-05-31 | 1980-12-04 | Boehringer Mannheim Gmbh | Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
| US4400381A (en) * | 1981-07-31 | 1983-08-23 | Laroche-Navarron, S.A. | Piperazine derivatives of theophylline |
-
1981
- 1981-08-31 US US06/298,227 patent/US4426383A/en not_active Expired - Fee Related
- 1981-09-02 NL NL8104073A patent/NL8104073A/nl not_active Application Discontinuation
- 1981-09-03 CH CH5675/81A patent/CH651042A5/fr not_active IP Right Cessation
- 1981-09-03 ES ES505184A patent/ES8303411A1/es not_active Expired
- 1981-09-03 SE SE8105240A patent/SE456910B/sv not_active IP Right Cessation
- 1981-09-03 DE DE19813134929 patent/DE3134929A1/de not_active Ceased
- 1981-09-03 GB GB8126653A patent/GB2083470B/en not_active Expired
- 1981-09-03 CA CA000385142A patent/CA1172632A/en not_active Expired
- 1981-09-04 IT IT23790/81A patent/IT1138196B/it active
- 1981-09-04 FR FR8116855A patent/FR2489331A1/fr active Granted
-
1983
- 1983-04-11 US US06/484,044 patent/US4564617A/en not_active Expired - Fee Related
-
1987
- 1987-11-20 SE SE8704599A patent/SE457083B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US4426383A (en) | 1984-01-17 |
| SE8704599D0 (sv) | 1987-11-20 |
| NL8104073A (nl) | 1982-04-01 |
| FR2489331B1 (enExample) | 1984-11-30 |
| ES505184A0 (es) | 1983-02-01 |
| SE8105240L (sv) | 1982-03-05 |
| CA1172632A (en) | 1984-08-14 |
| SE457083B (sv) | 1988-11-28 |
| IT1138196B (it) | 1986-09-17 |
| ES8303411A1 (es) | 1983-02-01 |
| FR2489331A1 (fr) | 1982-03-05 |
| SE456910B (sv) | 1988-11-14 |
| IT8123790A0 (it) | 1981-09-04 |
| GB2083470B (en) | 1984-09-12 |
| GB2083470A (en) | 1982-03-24 |
| DE3134929A1 (de) | 1982-06-09 |
| US4564617A (en) | 1986-01-14 |
| SE8704599L (sv) | 1987-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH651042A5 (fr) | Derives de la theophylline et de la theobromine, procede pour leur preparation et compositions pharmaceutiques contenant ces derives. | |
| US4289776A (en) | Xanthine derivatives | |
| LU84561A1 (fr) | 2-(4-((4,4,-dialcoyl-2,6-piperidinedione-1-yl)butyl)-1-piperazinyl)pyrimidines | |
| FR2521561A1 (fr) | Derives de benzisothiazole et benzisoxale piperazine | |
| EP0058146A1 (fr) | Nouveaux acides 2-(4-(diphénylméthyl)-1-pipérazinyl)-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques | |
| EP0377528B1 (fr) | Pipéridines, procédés de préparation et médicaments les contenant | |
| CH653021A5 (fr) | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. | |
| EP0254627B1 (fr) | Dérivés de la benzhydryloxyéthylpipérazine, procédés d'obtention et compositions pharmaceutiques les contenant | |
| EP0087810A1 (en) | Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient | |
| LU84562A1 (fr) | 2-(4-((4,4-dialcoyl-2,6-piperidinedione-1-yl)butyl)-1-piperazinyl)pyridines | |
| EP0048705B1 (fr) | Nouveaux acides 2-(4-(diphénylméthylène)-1-pipéridinyl)-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques | |
| EP0038784A2 (en) | 3,8-Dialkylxanthines, processes for their preparation and compositions containing them | |
| EP0034116A2 (en) | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | |
| FR2471381A1 (fr) | Derives de l'ergoline, procede pour les preparer et leur emploi comme medicaments | |
| CA2128202C (en) | Alkyl derivatives of trazodone with cns activity | |
| EP0301936B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
| LU86770A1 (fr) | Nouveaux derives de la purine,leur preparation et leur utilisation comme medicaments | |
| CH662354A5 (fr) | Derives de l'hydantoine, procede pour leur preparation et medicament contenant ces derives. | |
| US4250310A (en) | 3-[4-(3-Methoxy-phenyl)-piperazin-1-yl]-1-(furan-2-carbonyloxy)-propane | |
| FR2581064A1 (fr) | Derive antipsychotique a base de 8-(4-(4-(1-exo-1,2-benzisothiazol-3-yl)-1-piperazinyl)-butyl)-8-azaspiro(4,5)decane-7,9-dione et son procede de preparation | |
| US3092660A (en) | 1-acyl-2-alkyl-hydrazine derivatives | |
| EP0384843A2 (fr) | Dérivés de la 1-arylsulfonyl 2-pipéridinone, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
| FR2643373A1 (fr) | Nouveaux derives des bisarylalcenes, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0502110B1 (fr) | Derives d'(hetero) arylmethyloxy-4 phenyl diazole, leur procede de preparation et leur application en therapeutique | |
| FR2516510A1 (fr) | Derives de la (trimethoxy-3,4,5-cinnamoyl)-1-aminocarbonylethyl-4-piperazine substituee utilisables en pharmacie et procede pour leur preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |